Salzberg Marc, Thurlimann Beat, Hasler Ursula, Delmore Geoffrey, von Rohr Albert, Thurlimann Annatina, Ruhstaller Thomas, Stopatschinskaja Shanna, von Moos Roger
Pharma Brains, Basel, Switzerland.
Oncology. 2007;72(3-4):147-51. doi: 10.1159/000112731. Epub 2007 Dec 17.
Pegylated liposomal doxorubicin (PLD) has improved therapy options significantly, as it causes less myelosuppression, nausea, vomiting, and alopecia than conventional doxorubicin, while maintaining efficacy. The goal of this survey was to determine whether the use of PLD in a community-based patient group is comparable regarding chemotherapeutic doses and side effects to preselected study patients.
100 questionnaires were randomly sent to Swiss oncologists in private practices, general hospitals and university hospitals.
The patient cohort was heterogeneous with respect to prior treatments. PLD was an active agent in metastatic breast cancer and was well tolerated by the majority of patients. The most common non-hematological side effects were hand-foot syndrome (HFS) and mucositis while only patients receiving a dose of 50 mg/m(2) (recommended dose) experienced grade 4 HFS. The reported mean dose of PLD was 38.5 mg/m(2).
This community-based observational study supports previous reports indicating that PLD at a median dose of < or =40 mg/m(2) every 4 weeks is an active, well-tolerated agent in non-selected, pretreated patients with metastatic breast cancer.
聚乙二醇化脂质体阿霉素（PLD）显著改善了治疗选择，因为与传统阿霉素相比，它引起的骨髓抑制、恶心、呕吐和脱发较少，同时保持疗效。本次调查的目的是确定在社区患者群体中使用PLD在化疗剂量和副作用方面是否与预先选定的研究患者相当。
随机向瑞士私人诊所、综合医院和大学医院的肿瘤学家发送100份问卷。
患者队列在既往治疗方面存在异质性。PLD在转移性乳腺癌中是一种有效药物，大多数患者耐受性良好。最常见的非血液学副作用是手足综合征（HFS）和粘膜炎，而只有接受50mg/m²（推荐剂量）的患者出现4级HFS。报告的PLD平均剂量为38.5mg/m²。
这项基于社区的观察性研究支持先前的报告，表明每4周中位剂量≤40mg/m²的PLD在未选择的、经过预处理的转移性乳腺癌患者中是一种有效且耐受性良好的药物。
